“…As a result, eleven bioactive compounds (rosmarinic acid, citrusin C, nepetoidin B, tilianin, isoagastachoside, apigetrin, phlorizin, luteolin, diosmetin, apigenin, and acacetin-7- O -(3”- O -acetyl)-β- d -glucopyranoside) inhibited RANKL-induced osteoclast differentiation ( Figure 5 ). Similar to our results, previous studies have shown that rosmarinic acid inhibits RANKL-induced bone loss via suppression of p38-mediated osteoclast differentiation [ 44 ], and diosmetin decreases LPS-induced osteolysis via inhibition of ERK, JNK, and reactive oxygen species-mediated osteoclast formation and differentiation [ 45 ]. In addition, phlorizin, luteolin, and apigenin prevent OVX-induced postmenopausal bone loss [ 46 , 47 , 48 ].…”